This is a news story, published by Yahoo Finance, that relates primarily to Moderna news.
For more Moderna news, you can click here:
more Moderna newsFor more vaccine development news, you can click here:
more vaccine development newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about
sales growth. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest new products news, lowest annual revenue news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
ModernaReuters
•81% Informative
New product launches would drive an average annual growth rate of 25% in revenue between 2026 and 2028 .
Shares of Moderna were down 7% at $ 73.94 in premarket trading.
Company last month projected sales of $3 billion and $3.5 billion for this year .
Company has been banking on revenue from newer mRNA shots, including its RSV vaccine mRESVIA.
VR Score
92
Informative language
97
Neutral language
83
Article tone
formal
Language
English
Language complexity
46
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links